Literature DB >> 7826695

Enhancement of HIV type 1 infectivity in vitro by capsular polysaccharide of Cryptococcus neoformans and Haemophilus influenzae.

M Pettoello-Mantovani1, A Casadevall, P Smarnworawong, H Goldstein.   

Abstract

High concentrations of the cryptococcal capsular polysaccharide (CCP) are present in the serum, cerebrospinal fluid or both in the majority of AIDS patients infected with Cryptococcus neoformans. Because the prognosis of AIDS patients infected with cryptococcus is poor, we investigated whether the presence of CCP enhanced HIV-1 infection. The presence of CCP markedly increased the infectivity of HIV-1-infected H9 cells and subsequent production of infectious HIV-1 and formation of syncytia. In addition to enhancing the infectivity of H9 cells infected with laboratory isolates of HIV-1, the presence of CCP also increased the infectivity of peripheral blood mononuclear cells (PBMCs) infected with primary field strains of HIV-1. The in vitro infectivity of PBMCs from 20 of 44 HIV-1-infected individuals was significantly increased when cultured with CCP. Furthermore, HIV-1 was isolated from the PBMCs of three of these individuals only when cultured in the presence of CCP. CCP increased the binding of HIV-1 and recombinant gp120 to H9 cells and recombinant CD4, respectively. Thus, it is possible that the enhancement of HIV-1 infectivity by CCP is due to its capacity to increase the adherence of HIV-1 to target cells. Whereas the capsular polysaccharide of Haemophilus influenzae also markedly enhanced the infectivity of HIV-1, the capsular polysaccharides of C. freundii or S. flexneri had minimal effects on the infectivity of HIV-1. This indicated that the capacity to enhance HIV-1 infectivity was a property of polysaccharides from some pathogens and not others.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7826695     DOI: 10.1089/aid.1994.10.1079

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  10 in total

1.  Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.

Authors:  Robert A Larsen; Peter G Pappas; John Perfect; Judith A Aberg; Arturo Casadevall; Gretchen A Cloud; Robert James; Scott Filler; William E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 2.  Virulence factors of medically important fungi.

Authors:  L H Hogan; B S Klein; S M Levitz
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

3.  Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains.

Authors:  Thomas R Kozel; Stuart M Levitz; Françoise Dromer; Marcellene A Gates; Peter Thorkildson; Guilhem Janbon
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

4.  Serotypes of Cryptococcus neoformans isolated from patients prior to and during the AIDS era in Thailand.

Authors:  S Sukroongreung; C Nilakul; O Ruangsomboon; W Chuakul; B Eampokalap
Journal:  Mycopathologia       Date:  1996       Impact factor: 2.574

5.  Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes.

Authors:  C Retini; A Vecchiarelli; C Monari; F Bistoni; T R Kozel
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

Review 6.  Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection.

Authors:  S D Lawn; S T Butera; T M Folks
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

7.  Cryptococcus neoformans-astrocyte interactions: effect on fungal blood brain barrier disruption, brain invasion, and meningitis progression.

Authors:  Yeon Hwa Woo; Luis R Martinez
Journal:  Crit Rev Microbiol       Date:  2021-01-21       Impact factor: 7.624

8.  Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.

Authors:  D L Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Cryptococcal glucuronoxylomannan inhibits adhesion of neutrophils to stimulated endothelium in vitro by affecting both neutrophils and endothelial cells.

Authors:  Pauline M Ellerbroek; Andy I M Hoepelman; Floor Wolbers; Jaap Jan Zwaginga; Frank E J Coenjaerts
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

10.  Commentary: Role of Sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development.

Authors:  Luis R Martinez
Journal:  Front Microbiol       Date:  2015-10-09       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.